Induced Pluripotent Stem Cells (iPSC's) involve reprogrammed adult somatic cells usually derived from blood and skin cells, to mimic the self-renewal and pluripotent properties of Embryonic Stem Cells (ESC's) but not controversial as compared to (ESC's). Based on their ability to proliferate indefinitely and develop into any desired cell type such as heart, liver, neuronal and pancreatic cells, iPSC's have great potential to use in disease modeling, drug discovery & development, toxicology testing, regenerative medicine, and cell-based therapies.

The global Induced Pluripotent Stem Cells (iPSC) Market was valued at $1,841 million in 2020 and is estimated to reach $3,977 million by 2028, registering a CAGR of 10.2% from 2021 to 2028.

Factors that drive the market growth involve; Increase In Government and Private Investment Pertaining to iPSC: For Instance, the government of Japan has announced to invest approximately USD 250 million in the establishment of iPSC banks for use in the development of regenerative therapies. Furthermore, in 2019 M&A volume in the iPSC market rises to USD 1.9 Billion, including Bayer AG acquisition of BlueRock Therapeutics, Inc., and Semma Therapeutics acquisition by Vertex Pharmaceuticals for USD 950 Million.

The Surge in Number of Clinical Trials of iPSC: Since the first clinical trial in 2008, the number of iPSC's clinical trials has risen to 54 in 2021. Few of them are now advancing towards market approval, prominently CYP-004, a world-first Phase 3 iPSC-derived MSC's product by Cynata Therapeutics, and FT819, an iPSC-derived NK cell product by Fate Therapeutics.

Other factors that boost the market growth involve, the increase in public awareness, the surge in application of iPSC in therapeutics. However, high costs associated with the process, ethical issues, and potential tumor risk might hamper the market growth.

The report also presents a detailed quantitative analysis of the current market trends and future estimations from 2021 to 2028.

The forecasts cover By 6 Derived Cell Types, 6 Application Types, 2 End User Types, and 4 Regions.

The report comes with an associated file covering quantitative data from all numeric forecasts presented in the report.

The report has the following key findings:

• The global Induced Pluripotent Stem Cells (iPSC) Market accounted for $1,841 million in 2020 and is estimated to reach $3,977 million by 2028, registering a CAGR of 10.2% from 2021 to 2028.

• Based on derived cell type, Fibroblasts has accounted for the largest market share in 2020. It has accounted for more than 20% market share in 2020.

• In terms of application segment, Cell-based Therapies dominate in 2020. However, Disease Modeling is expected to grow at a higher CAGR over the forecast period.

• Biotechnology Companies have accounted for more than 65% market share in 2020. However, their market share is expected to decrease by 2028 due to the Academic and Research Institutes segment.

• North America has accounted for the largest market share in 2020 in the global Induced Pluripotent Stem Cells (iPSC). This is due to the increasing number of clinical trials and established infrastructure for the healthcare industry. The Asia Pacific is expected to grow at the fastest rate over the forecast period.

• By country, the U.S. is the largest revenue contributor in 2020. However, China is expected to grow at the highest rate over the forecast period.

The report covers the following topics:

• Market Drivers, Restraints, and Opportunities

• Key Developments, and Clinical Trials

• iPSC Competitive Landscape, Applications, Key Mergers & Acquisitions

• Analysis of by derived cell type, end-user, application, and Region

• COVID-19 Impact

• 25 Company Profiles, Product Portfolio, Financial Performance, and Key Strategies

• Market analysis and forecasts from 2021 to 2028

Click Here for another related report "CAR T-cell Therapy Market: 2020 - 2027"